ERBB2 and breast carcinoma: Ten of the 18 CDx assays are various qualitative assays for detecting HER2 expression or amplification in breast cancer; 2 are qualitative assays for BRAF V600E mutations; along with qualitative assays for ALK translocations, KRAS mutations and c-KIT; and 3 qualitative assays for EGFR mutations.